• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


ZEVR-Zephyr Valve Registry

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Progress Adequate
Application Number P180002 S005/ PAS001
Date Current Protocol Accepted 03/09/2022
Study Name ZEVR-Zephyr Valve Registry
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source Sponsor Registry
Comparison Group Concurrent Control
Analysis Type Descriptive
Detailed Study Protocol Parameters
Study Design Description Multi-center, single-arm, prospective Registry to be conducted at up to 10 clinical sites. Approximately 150 patients with severe emphysema undergoing Zephyr Valve treatment will be enrolled and followed out to 3 years. Assessments will be performed at 45-days, 6-months, 12-months, 24-months and 36-months post-procedure. The Zephyr Valve Registry will be conducted at a minimum of 5, and a maximum of 10 clinical sites. Enrollment is anticipated to be completed over 24 months. A minimum of 20 subjects treated with at least one Zephyr 5.5-LP EBV will be enrolled.
Study Population Description Adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation
Sample Size 150
Data Collection Safety endpoints:
Incidence rate of Pneumothorax at 45-days post-procedure.
Incidence rate of device/procedure related Serious Adverse Events (SAE) including but not limited to COPD exacerbations, pneumonia, hemoptysis, valve expectoration, valve migration and respiratory failure.
Effectiveness endpoints:
Treated Lobar Volume Reduction (TLVR) assessed by HRCT at 45-days.
Forced Expiratory Volume in 1 second (FEV1) at 6-months, 12-months, 24-months and 36-months.
6MWD at 6-months and 12-months.
SGRQ at 6-months and 12-months.
BODE Index at 6-months and 12-months.
Percent of patients with a TLVR of =350mL10,11.
Percent of patients with a TLVR of =563mL12.
Responder rates reported as percent of patients meeting the Minimal Clinically Important Difference (MCID) for each variable at 6-months and 12-months.
- MCID for FEV1: Increase of 10% (Liters)
- MCID for 6MWD: Increase of +25 meters
- MCID for SGRQ: Decrease of 4 points

Follow-up Visits and Length of Follow-up 36 months
Interim or Final Data Summary
Interim Safety Information Thirty-three (33) subjects of the planned 150 subjects for this study have reached the effectiveness data time point of 45-days post-procedure. Effectiveness data available currently is insufficient for analysis or to make any inferences.
Actual Number of Patients Enrolled 47
Actual Number of Sites Enrolled 9
Patient Follow-up Rate 47 subjects enrolled
33 completed 45 day follow up (70%)
1 completed 1 year follow up (2%)
Study Strengths & Weaknesses Too early in the follow up period to assess strengths and weaknesses

ZEVR-Zephyr Valve Registry Schedule

Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
6 month report 12/28/2019 12/18/2019 On Time
1 year report 06/28/2020 06/25/2020 On Time
2 year report 06/28/2021 06/28/2021 On Time
3 year report 06/28/2022 06/28/2022 On Time
4 year report 06/28/2023    

Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources